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1. Introduction
   Lung cancer is considered as the most common cancer in 
the word[1]. Until today, several biological events have been 
identified in lung adenocarcinoma, including epidermal 
growth factor receptor mutations and anaplastic lymphoma 
kinase translocations, offering new hopes to patients with 
metastatic disease. Lung cancer remains a major global 
health problem accounting for more than a million (1.8 
million) annual deaths worldwide[3,4], especially it kills more 
people than from colon, breast, and prostate cancers[5]. Lung 
cancer responsible for 17.8% of all cancer death[6]. In India, 
around 555 000 people died of cancer in 2010[7], according to 
estimates published in The Lancet today.  
2. Carcinogens of lung cancer
2.1. Smoking and lung cancer
   Lung cancer rates are largely determined by smoking 
patterns, medical, occupational and environmental 
radiation exposures have also been shown to increase 
risks of lung cancer[8]. The disease of lung cancer was not 
recognized as a disease until 1761[9], the first link between 
lung cancer and smoking was reported in 1929 by physician 
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Fritz Lickint from Germany. It is believed that smoking is 
the primary etiologic agent in more than 80% of lung cancer 
patients[10]. Cigarette smoking is also an important cause 
of esophageal, oral, oropharyngeal, hypopharyngeal and 
laryngeal cancers as well as pancreatic cancer, bladder 
cancer, and cancer of the renal pelvis including vascular 
diseases[11]. The mainstream smoke emerging from the 
mouth-piece of a cigarette is an aerosol containing about 
1 010 particles/mL and 4 800 compounds include poly 
aromatic hydrocarbons[12]. It is experimentally proved that, 
cigarette contains PAH like aza-arenes, tobacco-specific 
nitrosamines, e.g. 4-(methylnitrosamino)-1-(3-pyridyl)- 
1-butanone (NNK), 1,3-butadiene, ethyl carbamate, ethylene 
oxide, nickel, chromium, cadmium, polonium-210, arsenic, 
and hydrazine convincingly induce lung tumors[12]. Among 
the poly aromatic hydrocarbons, benzo[a]pyrene (BaP) is 
the most extensively studied compound against lung cancer 
through administration or inhalation[13]. Studies of non-
smokers exposed to second hand smoke in their workplace 
show an increased risk of lung cancer[14]. 
2.2. Radiation and lung cancer
   Lung cancer rates are also strongly associated with 
radiation, with an estimated excess relative risk per Gy of 
0.81 and excess absolute risk of 7.5 per 10 000 person-year 
Gy[15]. 
2.3. Pollution and lung cancer
   Pollution from transport also associated with the 
development of cancer, particularly lung cancer[16]. A recent 
report published in Europe related to relationship between 
lung cancer and vehicle-related pollution[17]. Exposure 
to NO2 from heavy traffic roads increases the risk of lung 
cancer[18,19]. Reasons for believing that air pollution might 
be an important factor in the development of lung cancer 
were first, the presence in polluted air of known human 
carcinogens[20]. Benzopyrene in air is one of the important 
risk factor of lung cancer[21,22]. Use of unprocessed solid 
fuel for cooking most found in India causes indoor air 
pollution which may have the wide-range of chemicals is 
the important risk factor of lung cancer[23, 24]. 
2.4. Chemicals and lung cancer
   Exposure to chemicals, whether naturally occurring 
or industrially produced, is a constant and inescapable 
fact of life. Natural chemicals such as arsenic, asbestos, 
chromium, nickel and vinyl chloride and to the natural 
radioactive gas radon increased the risk of lung cancer[25]. 
Genetic predisposition: especially polymorphisms of the 
tumor suppressor genes and the allelic variants of the 
genes involved in detoxification are implicated into the 
susceptibility to the disease. Chemical carcinogens has 
specific effect on metabolic pathways by interfering with the 
genetic integrity[26]. 
2.5. Radon and lung cancer
   Radon is an invisible, odorless, and tasteless radioactive 
gas that occurs naturally in soil and rocks. Radon-222 is 
a naturally occurring gas that originates from the decay 
product of uranium-238, and in turn decays into short-
lived radioactive alpha and beta emitting particles[27]. 
Exposure to radon (in mines or even houses) can cause 
damage to the lungs that may lead to lung cancer[28]. In 1988, 
radon was classified as a Class 1 human carcinogen and it 
is established that high levels of inhalation exposure can 
cause lung cancer[29]. Since radon is an inert gas, when it is 
inhaled, the gas is mostly exhaled except radon will decay 
to other radioactive decay products, such as polonium, 
bismuth and lead. These are solid fine radioactive particles 
that can be inhaled and subsequently reside in the lung. 
The link between radon and lung cancer dates back to early 
reports of underground miners in the 16th century who were 
anecdotally observed to have greater risk of respiratory 
related mortality, later determined to be lung cancer[30]. 
2.6. Asbestos and lung cancer
   Asbestos (actinolite, amosite, anthophyllite, chrysotile 
and tremolite) is the name of a group of minerals that occur 
naturally as fibers and are used in certain industries. 
Asbestos is one of the most important occupational 
carcinogens causing about half of the deaths from 
occupational cancer. When the particles are inhaled, they 
can lodge in the lungs, damaging cells and increasing the 
risk for lung cancer[31]. 
2.7. Lung diseases and lung cancer
   Certain lung diseases, such as tuberculosis, increase the 
risk of developing lung cancer. Lung cancer tends to develop 
in areas of the lung that are scarred from tuberculosis[32].
3. Symptoms of lung cancer
   Lung cancer symptoms are not often felt until the disease 
has developed into an advanced stage. Constant chest pain, 
chronic cough, coughing up blood (hemoptysis), dyspnea 
(difficulty breathing), fatigue, lung infection (pneumonia, 
bronchitis), shortness of breath, swollen lymph nodes, loss 
of appetite and weight loss, and wheezing, bone pain and 
tenderness, breast development in men, weakness, chills, 
speech difficulties or changes (i.e., hoarseness), droopy 
eyelids, swelling of the face and neck, fever, joint pain and 
swelling, muscle weakness, pale or bluish skin etc[33,34].
4. Apoptosis
   Apoptosis is a genetically programmed process 
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of cell death required for maintaining homeostasis 
under physiological conditions and for responding to 
various internal and external stimuli. Cells committed 
to apoptosis are characterized by membrane blebbing, 
cytoplasmic shrinkage, nuclear chromatin condensation 
and DNA fragmentation. Cancer cells have developed 
novel mechanisms for evading chemotherapy-induced 
apoptosis[35].
 
5. Molecular biology of lung cancer
   It has been broadly recognized that cancer is a disease 
caused by molecular alterations in either proto-oncogenes 
or tumor suppressor genes. In order to make an impact 
on lung cancer, we must understand the molecular 
abnormalities to target better therapeutics. Lung cancers 
exhibit multiple genetic lesions including mutations 
activating the dominant cellular proto-oncogenes as well as 
those inactivating the tumor suppressor genes. It is generally 
accepted that the pathogenesis of human cancer involves 
the accumulation of multiple molecular abnormalities over 
time. Those alterations lead to acquired cellular capabilities 
that can be classified in the following six functional sets: 1) 
self-sufficiency in growth signals due to mutations in proto- 
oncogenes, 2) insensitivity to anti-proliferative signals as a 
result of mutations affecting the tumour suppressor genes, 
3) evading of apoptosis by up-regulation of anti-apoptotic 
or down-regulation of pro apoptotic molecules, 4) limitless 
replicative potential due to the activation of telomerase, 
5) sustained angiogenesis and 6) capability for tissue 
invasion and capability for dissemination into distant sites 
(metastasis)[36]. 
5.1. Dominant and suppressor genes in lung cancer
   Lung cancer has majorly divided into small cell (small 
round cells in the lung) lung cancer (SCLC) and non-small 
cell lung cancer (NSCLC) (cells grow inside the lung other 
than the small cells). In 2011 NSCLC remains the principal 
cause of cancer-related death worldwide[37,38], accounting 
for more than one million deaths per year. These lung 
cancer cell can travel and spread to the other organs called 
as secondary cancer[39]. There are different oncogenes 
expressions have been investigated in NSCLC and SCLC. There 
are two forms of oncogenes: dominant oncogenes, exert their 
effect by overtaking the normal cellular growth function and 
tumor-suppressor genes, that exert their effect in controlling 
cellular growth[40]. 
5.2. Dominant oncogenes
   RAS genes (dominant) most frequently altered gene, with 
mutations occurring in 17%-25% of all cancers, 35% of 
lung cancers[41], which involve in the signal transduction 
and cell proliferation, which consist of K-RAS, H-RAS, and 
N-RAS. K-RAS was initially identified in a human lung 
cancer cell in 1982[42], and since then has been shown to 
be mutated in 35%-50% of all NSCLCs. RAS proteins are 
activated when it bind to guanosine triphophate (GTP) 
and inactivated by GTPase -activating protein (GAP) by 
hydrolyzing GTP to guanosine diphosphate (GDP). Mutations 
at or near the GTP-binding domain of RAS protein prevents 
the inactivation of GTP, thereby resulting in continuous RAS 
activity. Also GAP proteins have the transforming potential 
and responsible for point mutation at the codon 12 and 13 
in the encoding gene[43]. Unfortunately, in approximately 
50% of adenocarcinoma and for those harbouring K-RAS 
mutations, the most frequent mutation in Caucasian lung 
adenocarcinoma, so far no specific drug demonstrated 
efficacy. 
5.3. MYC genes
   Activation of this MYC (dominant) (c-MYC and N-MYC, 
and L-MYC) in lung cancer is gene amplification with 
resulting over-expression[44]. It is now well-established 
that the deregulated expression of c-myc plays a significant 
role in human cancer development. The c-Myc protein 
or the c-myc gene is overexpressed in a wide variety of 
human cancers. The universal deregulation of c-myc 
N-myc genes expression in tumor cells suggests that 
this oncogene represents an attractive target for cancer 
therapeutic purposes[45]. c-myc is expressed at elevated 
levels in most tumors[46]. In addition, several tumors contain 
genetic alterations (i.e., translocations, gene amplifications 
and mutations in regulators of c-myc expression), which 
directly affect c-myc expression. Unlike c- and N-myc, the 
evidence for a causal involvement of L-myc activation in 
human cancers is limited. In SCLC the frequency of L-myc 
amplification is rather low (~10%), and c- as well as N-myc 
amplifications also occur in SCLC. Mutational inactivation 
of the MYC antagonist Mxi-1 in prostate carcinoma may be 
another mechanism of MYC activation[47]. 
5.4. HER-2/NEU genes
   HER-2/NEU gene (proto-oncogene) is a growth factor 
receptor, over expression of these genes associated with 
an adverse prognosis in adenocarcinoma of the lung[48], 
and 4.BCL-2 (proto-oncogene) inhibit the programmed cell 
death/apoptosis, overexpressing cells have expansion of cell 
populations secondary to lack of apoptosis[49].
5.5. Tumor suppressor genes
   Tumor suppressor genes include those on chromosomes 
ip, lq, 3pl4, 3p2l.3, 3p25 (VHL gene), 5q21 (APCIMCC gene 
cluster), 9p21-Z2 (interferon gene cluster), lip, 13q (rb gene), 
i6p24, and i7p (p53 gene). In lung cancer chromosomal 
abnormalities (including loss of complete chromosomes or 
portions thereof) occur. In NSCLC, chromosomal aberrations 
have been described on 3p, 8p, 9p, 11p, 15p, and 17p with 
deletions of chromosomes 7, 11, 13, or 19. Also, in SCLC, 
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chromosomal abnormalities have been described on 1p, 3p, 
5q, 6q, 8q, 13q, or 17p[50]. Chromosomal abnormalities in lung 
cancer have been the loss of the short arm of chromosome 
3p[51]. The loss of alleles at 3p is observed in >90% of SCLC 
tumors and approx 50% of NSCLC tumors[52].  
5.6. p53 genes
   Its family includes p53, p73, and p63. The gene p53 located 
in the chromosome 17p13.1 encodes a nuclear protein that 
acts as a transcription factor and blocks the progression of 
cells through the cell-cycle late in the G1 phase. p53 gene 
mutations (deletion, point mutation and overexpression) 
cause a loss of tumor-suppression function, promoting 
cellular proliferation. Lung cancer, type of point mutation 
is a GC to TA transversion. Some of the p53 proteins also 
have transforming potential which can bind with normal p53 
and inactivate[53]. But in lung cancers, the p53 mutational 
patterns are different between G to T transversions and 
large fractions of the mutations are G to T events. The 
prevalence of G to T transversions is 30% in lung cancer 
but only 12% in normal and p53 mutations in lung cancers 
can be attributed to direct DNA damage[54]. Loss of the p53 
tumor suppressor pathway contributes to the development 
of most human cancers. These p53 tumor suppressor genes 
are mutated in over two thirds of lung cancers[55]. When 
mutated, p53 can function as an oncogene and accumulate 
in the cytoplasm[56]. Mutated p53 exhibits a prolonged half-
life and can thus be found to be overexpressed in about 50% 
of lung cancers by immunohistochemistry[57]. Mutations in 
p53 deactivate its transcriptional activity, while replacement 
of a wild-type p53 in lung cancer cells inhibits growth and 
tumorigenicity suggesting that p53 acts as a master growth 
regulatory switch[58-60]. Also the loss of heterozygosity 
involving several chromosome 3p regions accompanied by 
chromosome 3p deletions are detected in almost 100% of 
small (SCLCs) and more than 90% of non-small (NSCLCs) cell 
lung cancers which appear early in the pathogenesis of lung 
cancer[61].
   Perhaps as many as 10 or 20 genetic mutations have 
occurred by the time lung cancer becomes clinically 
evident[62-64]. The p53 gene probably works in the nucleus in 
complex with other proteins to act as a transcription factor 
to turn on a whole panel of tumor suppressor or growth 
regulatory genes[65-68]. p53 specifically binds to a consensus 
DNA binding sequence, consisting of repeats of the 10 bp 
motif 50-PuPuPuC(A/T)(T/A)GPyPyPy-30, located in the 
promoter or introns of its downstream target genes and thus 
transactivates the expression of these genes[69]. 
5.7. RB genes
   RB gene is a 105 kDa phosphoprotein located on the 
chromosome13q14.11, important in regulating the cell 
cycle during G0/G1 phase. A deletion of the RB gene and 
the abnormal expression of the tumor-suppressor gene 
RB may be an adverse prognosticator in SCLC. Chemical 
carcinogens activate NF-κB (nuclear transcriptional factor) 
inflammation-associated pathways, stimulating the anti-
apoptotic tumor inducing factors (STAT3) and pro-apoptotic 
tumor suppressor genes (ARF, p53)[70,71]. 
5.8. p16 and p15 Genes
   Certain lung cancer cells have a characteristic deletion of 
chromosome 9p21, from this region the genes have identified 
p16[72]and p15 and other genes on chromosome 3p also 
responsible for lung cancer was identified[73].
6. Recent research on chemotherapy
   Very few of the advances in chemotherapeutics have 
enhanced survival over the past decade. Treatment for 
cancer disease includes surgery, chemotherapy, radiation 
therapy or targeted drug therapy. Chemotherapy uses anti-
cancer drugs which kill the cancer cells it can improve the 
chance of living longer. One or more chemotherapy drugs 
may be given through intravenously or orally. A combination 
of drugs usually is given in a series of treatments over a 
period of weeks or months, with breaks in between so that 
you can recover. Chemotherapy can be used as a first line 
treatment for lung cancer or as additional treatment after 
surgery. In some cases, chemotherapy can be used to lessen 
side effects of cancer disease. 
   Chemotherapy is an important treatment for SCLC[74]. Use 
of chemotherapy with cisplatin plus etoposide is reported 
effective when the tumor is localized within the field of 
irradiation (limited disease),while cisplatin plus etoposide 
with chemotherapy has been the standard treatment for a 
long time.
   Several anticancer agents from tropical plants are in 
clinical use all over the world[75]. A recent trend in the 
chemotherapy for advanced lung cancer is the reports of 
efficacy of several regimens combining newly developed 
antineoplastic agents and platinum-based antineoplastic 
agents[76,77].
   The marine flora are rich source of medicinally important 
compounds predominantly belonging to polyphenols 
and sulphated polysaccharides. The chemicals have 
displayed an array of pharmacological properties especially 
antioxidant, immunostimulatory, and antitumour activities. 
The phytochemicals possibly activate macrophages, induce 
apoptosis, and prevent oxidative damage of DNA, thereby 
controlling carcinogenesis[78]. Even the marine flora 
especially mangrove resources enriched with chemicals, 
it has ration of unexplored for anticancer lead compounds. 
Around 45 mangroves and associated species like Acanthus 
illicifolius, Acanthus ebracteatus, Acrostichum aureum, 
Aegiceras corniculatum, Avicennia africana, A. nitida, 
Avicennia alba, Avicennia marina, Bruguiera exaristate, 
Bruguiera Sexangula, Barringtonia asiatica, Bruguiera 
cylindrica, Bruguiera gymnorrhiza, Buddleja parviflora, 
Bruguiera gymnorrhiza, Ceriops decandra, Ceriops tagal, 
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Cissus carnosa, Cordia cochinchinensis, Cynometra 
ramiflora, Calophyllum inophyllum, Derris trifoliata, 
Excoecaria agallocha, Flagellaria indica, Heritiera fomes, 
Ipomea pes-caprae, Lumnitzera racemosa, Nypa fruticans, 
Pandanus odoratissimu, Phoenix paludosa, Rhizophora 
mucronata, Rhizophora apiculata, Rhizophora stylosa, 
Sonneratia apetala, Sesuvium portulacastrum, Suaeda 
maritima, Sarcolobus globosus, Sonneratia alba, Sonneratia 
caseolaris, S. ovata, Stenochlaena palustris, Suaeda 
maritima, Trianthema decandra, Terminalia catappa, 
Xylocarpus granatum, Xylocarpus rumphii, Xylocarpus 
granatum, and Weddelia biflora reported to have anti-
cancer activity but very few studies only has been completed 
on lung cancer.
7. Conclusion
   Peoples are majorly concentrating research on terrestrial 
plants for long period. In recent years peoples are attracted 
by the mangrove species due to its rich source of medicinal 
properties with lot of pharmaceutical application. But much 
attention needs to find out the remedy for this serious global 
problem with lung cancer.
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   This is the study critically reviewed to understand the 
lung cancer in molecular level and the medicinal benefits of 
mangrove plants.
Related reports
   This is the innovative idea to find out the remedy for lung 
cancer from the mangroves. Number of related research 
has published but they were concentrated the terrestrial 
plants. A recent trend in the chemotherapy for advanced 
lung cancer is the reports of efficacy of several regimens 
combining newly developed antineoplastic agents and 
platinum-based antineoplastic agents.
Innovations and breakthroughs
   In this review, author pointed out number of innovative 
idea to find out the remedy for lung cancer. Also reviewed 
the lung cancer critically in molecular level which includes 
MYC genes (c-MYC and N-MYC, and L-MYC), HER-2/NEU 
genes, Tumor suppressor genes, p53 genes, RB genes and 
p16 and p15 genes. 
  
Applications
   In recent years peoples are attracted by the mangrove 
species due to its rich source of medicinal properties with 
lot of pharmaceutical application. But much attention needs 
to find out the remedy for this serious global problem with 
lung cancer to protect the human population.
Peer review
   This is the excellent review given by the author. This may 
help to understand the global problem lung cancer and to 
know the importance of chemotherapy; sofar 45 different 
mangrove plants have the anti-cancer potential but not 
studied thoroughly. This study clearly indicates the much 
more bottomless study need to find out the remedy for this 
problem and mangrove may be very good source. Also UGC, 
Government of India supported this brilliant study.  
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